Clinical trial · people
Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesity
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In a small, uncontrolled trial, setmelanotide lowered BMI and hunger in people whose obesity followed hypothalamic damage, and nausea and skin darkening were common.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 18
- Published
- 2024
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether daily setmelanotide could lower body mass index in people whose obesity followed damage to the hypothalamus, a part of the brain.
How the study was done
A phase 2, open-label trial at 5 US centers in 18 patients aged 6 to 40 years with obesity after a hypothalamic injury or a treated non-cancerous tumor in that area. Everyone got daily setmelanotide shots under the skin, raised up to 3.0 mg, for 16 weeks, with no placebo group. Results were compared with a historic rate of under 5% reaching the goal in this group.

Model. Individual results vary.
What they found
16 of 18 patients (89%) finished the trial and lowered their BMI (body mass index, a measure of weight for height) by at least 5%. Mean BMI fell by 15% (SD 10). Among patients aged 12 or older, hunger scores fell by a mean 45%. Common side effects were nausea (61%), vomiting (33%), skin darkening (33%) and diarrhea (22%). In a follow-on study, 12 patients treated for at least 12 months had a mean BMI change of -26% (SD 12) from the start.
What it doesn’t show
This was a small, 16-week trial with no placebo group, and everyone knew they were getting the drug, so results were judged against a historic rate rather than a direct comparison group. It was funded by Rhythm Pharmaceuticals.
The paper
Roth et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.